Potentiation of glutamate responses is a critical synaptic response to cocaine exposure in ventral tegmental area (VTA) neurons. However, the mechanism by which cocaine exposure promotes potentiation of NMDA receptors (NMDARs) and subsequently AMPA receptors (AMPARs) is not fully understood. In this study we demonstrate that repeated cocaine treatment causes loss of D2 dopamine receptor functional responses via interaction with lysosome-targeting G-protein-associated sorting protein1 (GASP1). We also show that the absence of D2 downregulation in GASP1-KO mice prevents cocaine-induced potentiation of NMDAR currents, elevation of the AMPA/ NMDA ratio, and redistribution of NMDAR and AMPAR subunits to the membrane. As a pharmacological parallel, coadministration of the high-affinity D2 agonist, aripiprazole, reduces not only functional downregulation of D2s in response to cocaine but also potentiation of NMDAR and AMPAR responses in wild-type mice. Together these data suggest that functional loss of D2 receptors is a critical mechanism mediating cocaine-induced glutamate plasticity in VTA neurons.
Introduction
Acute and long-term exposure to cocaine, results in adaptations in both NMDA receptors (NMDAR) and AMPA receptors (AMPAR) in ventral tegmental area (VTA) neurons, which underlie many of the long-term synaptic and behavioral effects of cocaine (Saal et al., 2003) . Specifically, acute cocaine ex vivo induces a potentiation of NMDAR excitatory postsynaptic currents (EPSCs), which is thought to result from an upregulation of NMDAR subunits, a postsynaptic effect (Schilström et al., 2006) . This acute potentiation of NMDARs, in turn, leads to enhanced AMPAR subunit translocation, within 3-5 h after cocaine perfusion or in vivo injection, resulting in AMPAR potentiation and an elevated AMPA/NMDA ratio (Ungless et al., 2001; Saal et al., 2003; Borgland et al., 2004; Argilli et al., 2008) . However, the precise mechanisms by which cocaine, whose primary target is the dopamine transporter (Giros et al., 1991; Kilty et al., 1991) , modulates glutamate receptors remains unclear.
The initial cocaine-induced NMDA potentiation has been proposed to occur as a consequence of cocaine-induced somatodendritic dopamine release (Zhang et al., 1994; Adell and Artigas, 2004) followed by activation of the D1-like D5 dopamine receptors, and stimulation of the cAMP-PKA pathway (Schilström et al., 2006) . However, VTA neurons express not only the G scoupled D5 dopamine receptor but also G i -coupled D2 receptors (Boyson et al., 1986; Mercuri et al., 1997; Ciliax et al., 2000; Khan et al., 2000) . This may be particularly relevant for cAMP-PKAdependent glutamatergic plasticity since D5 and D2 dopamine receptors have opposing effects on the cAMP-protein kinase A (PKA) pathway (Missale et al., 1998) . By extension, since changes in PKA activity modulate NMDAR potentiation, perturbations in the balance of these two dopamine receptor types would be expected to have an effect on glutamatergic synaptic plasticity in this brain region.
Following activation by dopamine, the D5 dopamine receptor undergoes endocytosis and recycling (Thompson and Whistler, 2011) , while the D2-type dopamine receptors are endocytosed and degraded through their interaction with the G-proteinassociated sorting protein 1 (GASP1; Bartlett et al., 2005) . This postendocytic sorting of D2 receptors by GASP1 has recently been shown to be critical for cocaine-mediated downregulation of D2 receptors in vivo (Thompson et al., 2010 ). Here we examined whether postendocytic downregulation of D2 receptors contributes to cocaine-mediated NMDAR and AMPAR potentiation in VTA neurons. We demonstrate that preventing the loss of D2 receptors, either in mice with a disruption of the GASP1 gene, or using aripiprazole (Abilify), a high-affinity D2 agonist that does not induce endocytosis and degradation of the D2 receptors
Electrophysiology
WT and GASP1-KO mice were injected only daily in their home cages with saline or cocaine (15 mg/kg, i.p.) or cocaine and aripiprazole (15 mg/kg, i.p. each). Horizontal brain slices of the VTA were prepared 24 h after mice received the last intraperitoneal injection of saline or cocaine. The mice were anesthetized with 5% isoflurane and immediately decapitated using a guillotine. Brain slices 190 m thick were cut in ice-cold modified artificial CSF (aCSF) solution. All solutions were saturated with 95% O 2 -5% CO 2 (carbogen). The composition of the solution contained the following (in mM): 85 choline Cl, 40 NaCl, 4 KCl, 1.25 NaH 2 PO 4 , 25 NaHCO 3 , 0.5 CaCl 2 , 7 MgCl 2 , 10 dextrose, 1 ascorbate, 3 Na pyruvate, and 3 myo inositol; osmolarity: 310 -320. Slices were recovered first for ϳ10 -15 min at 32°C in the cutting solution and were later transferred to recording aCSF of the following composition (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH 2 PO 4 , 1 MgSO 4 , 2 CaCl 2 , 25 dextrose, and 25 NaHCO 3 ; 295-300 osmolarity. Glutamate currents were recorded in the presence of picrotoxin (100 M) to block GABA A receptors.
Cells were visualized using an upright microscope with infrared illumination. We used an Axopatch 200 Amplifier (Molecular Devices) to perform whole-cell patch-clamp recordings with 2-6 M⍀ electrodes containing the following (in mM): 120 cesium methanesulfonic acid, 20 HEPES, 0.4 EGTA, 2.8 NaCl, 5 TEA-Cl, 2.5 NaATP, and 0.25 NaGTP, pH 7.2-7.4. The VTA neurons that were recorded in this study were characterized by the presence of I h , a current found in Ͼ98% of mouse VTA dopamine neurons (Wanat et al., 2008; Madhavan et al., 2010) . A bipolar stimulating electrode was placed 100 -300 m rostral to the recording electrode and afferents were stimulated at 0.1 Hz. The evoked EPSCs were filtered at 2 kHz, digitized at 5-10 kHz, and recorded using Igor Pro software (WaveMetrics). We held neurons at ϩ40 mV for recordings of NMDA-mediated EPSCs. AP-5 (50 M) was used to block NMDARs, while recording AMPA/NMDA ratios. Data were averaged in 2.5 min bins, normalized to baseline, which is defined as the average EPSC amplitude of 10 min before drug application, and presented as average across cells Ϯ SEM. The magnitude of the enhancement of the NMDAREPSCs during 30 consecutive sweeps taken 25-30 min after washout of the drug was used for comparison between groups. For long-term potentiation (LTP) experiments, evoked EPSPs were recorded from neurons current clamped at Ϫ65 to Ϫ70 mV using 3-5 M⍀ electrodes filled with a potassium gluconate solution containing the following (in mM): 115 potassium gluconate, 5 HEPES, 0.1 EGTA, 20 NaCl, 1.5 MgCl 2 , 2 NaATP, and 0.5 mM NaGTP, pH 7.3. LTP was induced by using a spike timingdependent (STD) protocol where 20 bursts of EPSP-spike pairs were delivered, with each burst consisting of five paired stimuli delivered at 10 Hz (interburst interval of 5 s) (Argilli et al., 2008) . The postsynaptic spikes were evoked ϳ5 ms after the onset of EPSPs by injecting depolarizing current pulses (1-2 nA, 3 ms).
To record the effect of quinpirole on G-protein-coupled inwardly rectifying K ϩ (GIRK) conductances, the potassium methanesulfonatebased internal solution consisted of 0.95% (v/v) KOH, 0.38% (v/v) methanesulfonic acid, 20 mM HEPES, 0.2 mM EGTA, 2.8 mM NaCl, 2.5 mg/ml NaATP, and 0.25 mg/ml NaGTP, pH 7.2-7.4, osmolarity 275-285. Neurons were visualized with an upright microscope equipped with infrared differential interference contrast using Axiovision camera and software (Carl Zeiss Microimaging) . aCSF at 30 -32°C was continuously perfused at 2-3 ml/min over brain slices.
Synaptosomal membrane preparation and Western blotting. VTA brain tissue was extracted from WT or GASP1-KO mice treated with saline or cocaine (15 mg/kg, i.p.), 24 h after the last injection. The tissue was homogenized manually in an ice-cold buffer containing 10 mM Trisacetate, 5 mM EDTA, 0.32 M sucrose, and protease and phosphatase inhibitor I and II. The homogenate was centrifuged at 1000 ϫ g for 10 min at 4°C to pellet heavy membranes and debris (P1). The supernatant (S1) was collected and centrifuged at 16,000 ϫ g at 4°C for 20 min to pellet the synaptosomal membrane fraction (P2). P2 was resuspended and protein concentration was estimated. Protein (20 g) was resolved by NuPage 4 -12% Bis-Tris gel and transferred to a PVDF membrane. Membranes were probed with the appropriate antibodies to NMDAR subunits: NR1 (mouse anti-NR1; Millipore, 1:500), NR2B (rabbit anti-NR2B; Millipore, 1:1000), NR2A (rabbit anti-NR2A; Cell Signaling Technology, 1:1000); AMPAR subunit: GLUA1 (mouse anti-Glur1; Santa Cruz Biotechnology, 1:500), and ␤-actin (mouse anti-␤-actin; Sigma, 1:20,000). Secondary antibodies used were the IRDye 800CW goat anti-rabbit or anti-mouse (LI-COR Biosciences, 1:15,000). The LI-COR Odyssey system was used for fluorescent imaging and quantification of the Western blots.
Data analysis. Data analysis was performed using GraphPad Prism or Microsoft Excel. Data are represented as mean Ϯ SEM, unless specified; t tests or one-way ANOVA was used to compare data for significance (***p Ͻ 0.001, **p Ͻ 0.01; *p Ͻ 0.05; ns p Ͼ 0.05).
Results

Cocaine induces loss of D2 dopamine receptor response in VTA neurons
Application of a saturating dose of quinpirole (3 M), a D2-type dopamine receptor agonist, induces activation of a hyperpolarizing potassium (GIRK) conductance in VTA neurons ( Fig. 1 A, D ; peak effect in WT: 18.97 Ϯ 2.07 mV, n ϭ 5). Treatment of WT mice with cocaine (15 mg/kg, 5 d, once daily) resulted in a significant reduction in the activation of this GIRK conductance by quinpirole ( Fig. 1 A, D ; peak effect in WT cocaine: 7.58 Ϯ 0.66 mV, n ϭ 5; comparing with WT: p ϭ 0.0008; t (1,8) ϭ 5.24) suggesting that repeated treatment with cocaine induces a loss in the functional effect of D2 dopamine receptors in VTA neurons.
We next examined the effects of repeated cocaine on D2 receptor function in mice with a genetic disruption of GASP1 (GASP1-KO). Quinpirole induced a GIRK conductance in VTA neurons from the GASP1-KO mice indistinguishable from that in WT mice ( Fig. 1 B, D ; peak effect in GASP1-KO: 20.34 Ϯ 2.01 mV, n ϭ 5; comparing with WT: p ϭ 0.65; t (1, 8) ϭ 0.48). However, repeated cocaine treatment produced a significantly reduced loss of D2 responses in GASP-KO mice. (Fig. 1C,D ; peak effect in GASP1-KO cocaine: 13.04 Ϯ 1.05 mV, n ϭ 5; with WT cocaine: p ϭ 0.002; t 1,8) ϭ 4.41). Thus, the functional effects of D2 receptors are likely to be maintained in the GASP1-KOs even after repeated cocaine. This is supported by biochemical evidence of both in vitro and in vivo downregulation of D2 dopamine receptors likely mediated, at least in part, by an interaction of the receptors with GASP1 (Bartlett et al., 2005; Thompson et al., 2010) .
Absence of cocaine-induced NMDA potentiation in GASP1-KO mice
Cocaine perfusion in VTA slices induces a PKA-dependent timedelayed potentiation of NMDA EPSCs, a response that has been shown to require activation of the G s -coupled D5 receptor (Schilström et al., 2006) . However, the role of the G i -coupled D2-type dopamine receptors and, in particular, whether functional loss of D2 receptors, which occurs in a time course consistent with the delay in potentiation, was important for the potentiation has not been examined. Perfusion of cocaine (5 M) resulted in a delayed potentiation of NMDA EPSCs (Fig. 2 A, C; percentage NMDA potentiation in WT (gray bar): 136.81 Ϯ 14.26, n ϭ 11) as previ-ously reported. Repeated cocaine treatment in vivo produced a greater elevation in the potentiation induced by cocaine in vitro ( Fig. 2 A, C; percentage NMDA potentiation in WT cocaine (gray bar): 174.02 Ϯ 7.78, n ϭ 8; comparing with WT: p ϭ 0.055; t (1,17) ϭ 2.06), suggesting that cocaine-induced loss of D2 receptors could enhance cocaine-mediated NMDAR potentiation. However, treatment of WT mice with quinpirole (5 mg/kg, i.p., 1 d), was not sufficient to exacerbate the in vitro cocaine-induced potentiation of NMDA EPSCs ( Fig. 2 A, C; percentage NMDA potentiation in WT quinpirole (gray bar): 144.4 Ϯ 7.77, n ϭ 5; comparing with WT: p ϭ 0.74; t (1, 14) ϭ 0.34). Together, we find that while loss of D2 receptor function is necessary to produce cocaineinduced NMDA potentiation, it is not sufficient to do so.
Potentiation of NMDARs in response to cocaine in the VTA slice is thought to occur via a rearrangement of NMDAR subunit composition in these neurons (Schilström et al., 2006) . Specifically, cocaine has been shown to produce an increased synaptic expression of both the obligatory NR1 subunit and the NR2B subunit (Schilström et al., 2006) . Here, we likewise found that repeated cocaine produced a significant increase in NR1, NR2B, and NR2A levels in WT mice (Fig. 2 D, E ; percentage change WT cocaine; NR1: 159.4 Ϯ 13.81, n ϭ 8, p ϭ 0.004; t (1,7) ϭ 4.3; NR2B: 250.8 Ϯ 42.63, n ϭ 12, p ϭ 0.005; t (1,11) ϭ 3.54; NR2A: 193.6 Ϯ 30.55, n ϭ 8, p ϭ 0.02; t (1,7) ϭ 3.06).
Next, we examined whether removal of GASP1 altered cocaine-induced NMDAR potentiation. Perfusion of cocaine did not produce a potentiation of NMDA EPSCs in GASP1-KO mice, neither in naive mice, nor in mice pretreated with repeated cocaine (Fig. 2 B, C; percentage NMDA EPSC in GASP1-KO (gray bar): 90.29 Ϯ 9.25, n ϭ 12; WT vs GASP1-KO: p ϭ 0.011; t (1,21) ϭ 2.78; percentage NMDA EPSC in GASP1-KO cocaine: 68.3 Ϯ 10.47, n ϭ 6; WT vs GASP1-KO cocaine: p ϭ 0.005; t (1,15) ϭ 3.26). Furthermore, in the GASP1-KO mice, cocaine treatment did not produce significant changes in the NR1 and NR2B subunit expression, and produced a decrease rather than an increase in NR2A expression (Fig. 2 F, G; percentage change GASP1-KO cocaine; NR1: 73.55 Ϯ 14.85, n ϭ 6, p ϭ 0.14; t (1,5) ϭ 1.78; NR2B: 103.1 Ϯ 12, n ϭ 8, p ϭ 0.8; t (1,7) ϭ 0.26; NR2A: 75.55 Ϯ 5.71, n ϭ 6, p ϭ 0.008; t (1,5) ϭ 4.28), consistent with the observed lack of NMDA potentiation by cocaine in GASP1-KO mice. Reducing the functional downregulation of D2 receptors in response to cocaine prevents changes in NMDAR function associated with cocaine exposure.
Absence of AMPAR potentiation in cocaine-treated GASP1-KO mice
Cocaine-induced changes in NMDA subunit composition have been shown to result in a cascade of events that produce reciprocal potentiation of AMPA EPSCs that is measured as an elevated AMPA/ NMDA ratio (Argilli et al., 2008) . Changes in AMPA/NMDA ratio are time locked to the cocaine-induced changes in NMDAR, as they are blocked by the NMDAR antagonist AP-5 (Argilli et al., 2008 ). An increase in the AMPA/NMDA ratio is thought to underlie long-term synaptic and behavioral responses to cocaine . Thus, we examined the effect of repeated cocaine treatment on AMPA/ NMDA ratios in both WT and GASP1-KO mice. We observed a significant elevation in AMPA/NMDA ratios in WT mice after repeated cocaine treatment (Fig. 3 A, B,E; AMPA/NMDA WT saline: 0.43 Ϯ 0.11, n ϭ 5; AMPA/NMDA WT cocaine: 1.39 Ϯ 0.15, n ϭ 4; p ϭ 0.001; t (1,7) ϭ 5.19). This effect on the AMPA/NMDA ratio is thought to be mediated by an increased insertion of the AMPAR subunit GLUA1 after cocaine (Huang et al., 2009; Lüscher and Malenka, 2011) . Consistent with this hypothesis, repeated cocaine resulted in a significant elevation in GLUA1 receptor expression in the VTA (Fig. 3 F, G ; percentage change WT cocaine; GLUA1: 210.1 Ϯ 28.32, n ϭ 12, p ϭ 0.002; t (1,11) ϭ 3.89).
In contrast, in GASP1-KO mice, there was no elevation in AMPA/NMDA ratio after repeated cocaine ( Fig. 3C-E ; AMPA/ NMDA GASP1-KO saline: 0.98 Ϯ 0.17, n ϭ 6; AMPA/NMDA GASP1-KO cocaine: 0.78 Ϯ 0.15, n ϭ 4; p ϭ 0.43; t (1,8) ϭ 0.84). Furthermore, cocaine did not produce an increase in GLUA1 subunit expression in GASP1-KO mice. In fact, we observed a reduction in GLUA1 subunit expression levels in these mice after repeated cocaine (Fig. 3 H, I ; percentage change GASP1-KO cocaine; GLUA1: 68.21 Ϯ 3.98, n ϭ 8, p Ͻ 0.0001; t (1,7) ϭ 7.98), consistent with the trend toward a decrease in the AMPA/NMDA ratio after repeated cocaine in the GASP1-KO mice.
These data further support the view that cocaine-induced NMDA potentiation drives a reciprocal elevation in AMPA/ NMDA. Furthermore, since neither of these adaptive changes occurs in GASP1-KO mice, these data indicate that functional downregulation of D2 receptors is a trigger for the adaptations in glutamate receptor responsiveness and subunit specification on VTA neurons. 
STD LTP induction occurs in WT and GASP1-KO
We next examined whether the lack of cocaine-mediated changes in the AMPA/NMDA ratio was a consequence of the somewhat higher baseline levels of AMPARs (Fig. 3C ). Specifically, we tested whether the higher levels of AMPARs at baseline in the GASP1-KO occludes further potentiation by recording STD LTP induction in both WT and GASP1-KO VTA neurons. WT VTA neurons showed robust STD LTP induction (Fig. 4 A, C ; 154 Ϯ 18.8% at the 30 -35 min time points, n ϭ 6 cells). GASP1-KO VTA neurons also showed robust STD LTP induction (Fig. 4 B, D; 147.6 Ϯ 9.5% at the 30 -35 min time points, n ϭ 6 cells), which was not significantly different from WT STD LTP induction ( p ϭ 0.77, t (1,10) ϭ 0.3). Consequently the lack of cocaine-induced potentiation in GASP1-KO mice is unlikely a consequence of synaptic occlusion.
D2 dopamine receptor downregulation underlies cocaineinduced changes in glutamate EPSCs
GASP1 controls the postendocytic sorting of several G-proteincoupled receptors. Thus, to specifically address whether maintenance of functional D2 receptors in the GASP1-KO mice was responsible for preventing cocaine-induced changes in glutamate responses, we used an alternative pharmacological strategy. Aripiprazole is a high-affinity partial agonist at the D2 dopamine receptors approved for human use as an atypical antipsychotic and antidepressant (Lawler et al., 1999; Mazza et al., 2009; Shelton et al., 2010) . Aripiprazole activates G i signaling from D2 receptors and has an affinity for the D2 receptor nearly 500-fold higher than dopamine (Burris et al., 2002) . However, aripiprazole-activated D2 receptors are not recruited for endocytosis or downregulated due to their inability to induce significant ␤-arrestin recruitment (Klewe et al., 2008; Masri et al., 2008; Allen et al., 2011) . We hypothesized that coapplication of aripiprazole with cocaine would maintain G i signaling through D2 receptors but prevent their functional downregulation in response to cocaine. Indeed, we found that repeated treatment with a mixture of aripiprazole and cocaine (15 mg/kg each for 5 d, once daily) prevented the functional downregulation of D2-GIRK responses in VTA neurons ( Fig. 5A ; peak effect in WT cocaine ϩ aripiprazole: 15.07 Ϯ 2.18 mV, n ϭ 5; comparing with WT cocaine: p ϭ 0.01; t (1, 8) ϭ 3.29). Furthermore, coapplication of aripiprazole (5 M) and cocaine (5 M), did not result in a potentiation of NMDA EPSCs that was observed with cocaine alone (compared with WT cocaine: p Ͻ 0.0001; t (1,12) ϭ 8.83). Instead, coapplication of aripiprazole and cocaine had a significant depressive effect on the NMDA EPSCs compared with saline ( Fig. 5B ; percentage NMDA potentiation in WT cocaine ϩ aripiprazole (gray bar): 89.95 Ϯ 13.72, n ϭ 6; p ϭ 0.048, t (1,15) ϭ 2.14). Most importantly, repeated treatment with cocaine and aripiprazole (15 mg/kg each for 5 d, once daily), did not induce an elevation of AMPA/NMDA responses, in contrast to repeated cocaine alone ( Fig. 5C ; AMPA/ NMDA WT cocaine ϩ aripiprazole: 0.89 Ϯ 0.10, n ϭ 7; p ϭ 0.02; t (1,9) ϭ 2.82). In contrast, repeated treatment of mice with cocaine and quinpirole (15 mg/kg cocaine and 5 mg/kg quinpirole for 5 d, once daily), a D2 agonist that does drive D2 receptor downregulation (Thompson et al., 2010) , produced a substantial potentiation of the AMPA/NMDA ( Fig. 5D ; AMPA/NMDA WT cocaine ϩ quinpirole: 3.18 Ϯ 1.06, n ϭ 6; comparing with WT cocaine ϩ aripiprazole: p ϭ 0.04; t (1,11) ϭ 2.34; comparing with WT cocaine: p ϭ 0.21; t (1, 8) 
Together, we show evidence that reducing cocaine-mediated loss of the D2 receptor responses, using a biased D2 receptor agonist that does not promote D2 receptor endocytosis, has equivalent protective effects for preventing cocaineinduced glutamatergic synaptic plasticity as the genetic disruption of GASP1.
Discussion
In this study, we have demonstrated a critical role of D2 dopamine receptor loss in mediating cocaine-induced synaptic potentiation of AMPAR and NMDAR EPSCs in VTA neurons. This loss of D2 receptors is likely mediated by postendocytic degradation by GASP1 binding, since both disruption of GASP1 and pre- vention of D2 receptor endocytosis by aripiprazole prevent the cocaine-induced changes in glutamatergic potentiation. These cocaine-induced changes in glutamate potentiation are thought to play a critical role in the development of behaviors associated with cocaine abuse and addiction (Bowers et al., 2010; Lüscher and Malenka, 2011) . Indeed, pharmacological blockade of NMDARs in the VTA prevents the acquisition of locomotor sensitization and conditioned place preference (CPP) to cocaine (Kalivas and Alesdatter, 1993; Harris and Aston-Jones, 2003) . Additionally, removal of functional NMDARs from dopamine neurons in the VTA also impairs cocaine CPP (Zweifel et al., 2008) . Changes in NMDA potentiation modulate AMPAR function and subunit upregulation, in an NMDAR-dependent fashion, resulting in an increase in AMPA/NMDA ratio or AMPAR potentiation (Argilli et al., 2008) . Elevation of the AMPA/NMDA ratio, a cellular hallmark of drug abuse, occurs both during passive cocaine exposure and active self-administration, and is thought to orchestrate long-term synaptic plasticity in response to cocaine (Ungless et al., 2001; .
Our goal in these studies has been to identify the cellular mechanisms mediating cocaine-induced changes in glutamate receptors. Cocaine exposure is thought to result in a local increase in dopamine levels around the soma of VTA neurons (Zhang et al., 1994) , which is worsened by inefficient reuptake processes in the presence of cocaine (Iravani et al., 1996) . Prior evidence indicated a critical role of cAMP-PKA signaling from the D1-type, D5 dopamine receptor for the changes in NMDA and AMPA function after cocaine exposure in the VTA. Nevertheless, VTA neurons express not only dopamine D5 but also D2 receptors, which have opposing effects on PKA activity. Furthermore, D2 dopamine receptors present on the cell bodies of VTA neurons also likely modulate the action potential duration in these neurons (Margolis et al., 2008) . Thus, it is reasonable to hypothesize that D2 receptor signaling could also be an important modulator of cocaineinduced glutamate plasticity. In fact, the D2 antagonist eticlopride, when coapplied with cocaine, results in an earlier rise time for NMDA potentiation and a marginal increase in amplitude of the responses (Schilström et al., 2006) suggesting that activity at D2 opposes the action at D5.
Indeed, one of the most well established molecular hallmarks of drug abuse is a loss of dopamine D2 receptor availability (Chen et al., 1993; Moore et al., 1998; Jones et al., 1999; Attarbaschi et al., 2007) . However, the molecular mechanisms responsible for downregulation of D2 receptors and the consequences of this downregulation for cellular physiology have remained unclear. D2-type dopamine receptors are targeted for degradation in the lysosome after endocytosis through their interaction with GASP1 both in vitro and in vivo (Bartlett et al., 2005; Thompson et al., 2010) and GASP1-KO mice do not show cocaine-induced downregulation of D2 receptors. Importantly, GASP1-KO mice also show reduced locomotor sensitization to cocaine (Thompson et al., 2010) , a reduction in acquisition of cocaine self-administration (Boeuf et al., 2009 ) and deficits in motivation (Mathis et al., 2011) . Together, these data suggest that D2 receptor hypofunction is important for diverse behavioral effects of cocaine.
In this study we provide mechanistic insight into how functional downregulation of D2-type dopamine receptors after re- peated cocaine exposure could affect drug-induced behavior. We hypothesized that loss of D2 receptors through postendocytic degradation, and the consequent change in the balance of D5 and D2 signaling, would be necessary for cocaine-induced glutamatergic plasticity. We show that, in the absence of GASP1, D2 receptors in the VTA are not substantially downregulated functionally. We further show that maintenance of D2 receptor signaling prevents cocaine-induced NMDA potentiation, increases in the AMPA/NMDA ratio, and the concomitant increases in NMDA and AMPA subunit expression levels. Importantly, we show that the GASP1-KO synapses are not prepotentiated or occluded to further potentiation, as the induction of STD LTP in these synapses are not significantly different compared with WT synapses.
Together these data suggest that loss of D2 receptor function is necessary to produce cocaine-induced changes in glutamatergic plasticity. Nevertheless, it is clear that signaling from D5 receptors is also necessary, since pretreatment with quinpirole, a D2 receptor agonist, does not result in a sizable increase in the cocaine-induced NMDA EPSCs compared with saline-treated mice. In short, our studies suggest that restoration of the balance of D2 and D1 signaling prevents changes in glutamatergic plasticity that accompanies chronic drug use. We used two methods to maintain D2 receptor levels, one genetic-the GASP1 KO mice, and one pharmacological-using the noninternalizing high-affinity D2 receptor agonist aripiprazole, which has been shown recently to block cue-conditioned and cocaine-primed reinstatement of cocaine seeking (Feltenstein et al., 2007) . Importantly, the effects of aripiprazole on cocaine-induced plasticity were not replicated by cotreatment with quinpirole, another high-affinity D2 receptor agonist that does induce endocytosis and loss of D2 receptors. Thus, preventing the loss of D2 receptors, not merely providing tone through D2 receptors, was necessary to block cocaine-induced glutamatergic plasticity. The GASP1-D2 interaction could be a novel target for the treatment of drug abuse. Additionally, the efficacy and safety profile of aripiprazole for disease indications including schizophrenia and depression may reflect its ability to restore the balance of D2 and D1 signaling, by providing agonist tone through D2 receptors without causing their downregulation. In this way, aripiprazole is not merely a substitute for dopamine or D2 agonists such as quinpirole, which do cause D2 downregulation. In conclusion, here we identify a molecular mechanism, GASP1-mediated downregulation of D2 dopamine receptors, which is responsible, at least in part, for drug-induced changes in glutamatergic plasticity in dopamine neurons of the VTA. Identifying this mechanism not only provides insight into why drug abusers of all kinds show low D2 receptor availability, but also highlights the potential utility of an FDA-approved pharmacological agent that could prove to be useful in the treatment of drug abuse.
